|
|
Article: Inex's NHL Drug Proves Strong In Final Phase II/III Study Data.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Disclosing final data from the pivotal Phase II/III trial with its anticancer drug Onco TCS, Inex Pharmaceuticals Corp. said the outcome reinforces good news suggested by the first look at results in December.
"There's been no material change and the numbers even have gone up a little bit," said David Main, president and CEO of Vancouver, British Colombia-based Inex, which tested the product in 119 patients with relapsed aggressive non-Hodgkin's lymphoma.
"We'll be filing our [new drug application with the FDA] toward the end of the third quarter or early in the fourth," Main told BioWorld Today, repeating earlier guidance.
...